Fig. 1: HLA-DR4^{Vim-64cit59-71}- and HLA-DR4^{α-eno-15cit10-22}-specific CD4⁺ T cells in immune HLA-DR4 transgenic mice.

a Representative HLA-DR4^{Vim-64cit59-71} and HLA-DR4^{α-eno-15cit10-22} tetramer staining on CD4⁺ T cells from the draining lymph nodes (dLN) of HLA-DR4 mice immunized 8d previously with a 50:50 mix of Vimentin64cit_{59-71 and} α-enolase-15cit_10-22 peptides (upper plots) or PBS (lower plots) emulsified in CFA. Gating strategies shown in Supplementary Fig. 1. Numbers in dot plots represent total number of CD4⁺ tetramer⁺ cells after magnetic enrichment and acquisition of entire sample. b Frequency of CD4⁺ HLA-DR4^{Vim-64cit59-71} (Vim-64cit)- or HLA-DR4^{α-eno-15cit10-22} (α-eno-15cit)-tetramer positive CD4⁺ cells in the dLN of mixed peptide- (closed symbols; n = 4) or PBS- (open symbols; n = 2) immunized HLA-DR4 mice. Symbols represent data from individual mice obtained in two independent experiments. Horizontal bars indicate mean ± SD. c HLA-DR4^{Vim-64cit59-71}- and HLA-DR4^{α-eno-15cit10-22}-specific TCRαβ repertoires isolated from the dLN of a peptide-immunized HLA-DR4 mouse (n = 1 with 32 and 63 sequences, respectively), showing the frequency of individual clones and the TCR gene segment usage and CDR3 amino acid sequence for each clone. CDR3 nucleotide sequences are listed in Supplementary Table 10. TCRs marked A07, A03, E02, E04 and E17 were selected for further analysis. d 293 T cells transiently co-transfected with a HLA-DR4^{Vim-64cit59-71} specific TCR (A03 and A07) or HLA-DR4^{α-eno-15cit10-22} specific TCR (E02, E04, E17) and CD3γδεζ were stained with either HLA-DR4^{Vim-64cit59-71} tetramer (red), HLA-DR4^{α-eno-15cit10-22} tetramer (orange) or control HLA-DR4^{Fibβ-74cit69-81} tetramer (charcoal). Source data are provided as a Source Data file.